Loading
Life sciences · Journal article
Annual Review of Medicine · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
T cell receptor–engineered T (TCR-T) cell therapy has emerged as a promising adoptive cellular therapy for solid tumors by enabling recognition of intracellular antigens presented via human leukocyte antigen (HLA) molecules. Unlike chimeric antigen receptor T cell therapy, TCR-T cell therapy targets a broader antigen repertoire, including cancer-testis antigens, neoantigens, and viral antigens. Recent clinical advances, highlighted by the approval of afamitresgene autoleucel in synovial sarcoma, demonstrate meaningful antitumor activity. However, several limitations remain, including HLA restriction, antigen heterogeneity, toxicity related to on-target/off-tumor effects, and mechanisms of resistance such as antigen loss and T cell exhaustion. Advances in antigen selection, gene editing, and synthetic biology are improving both safety and efficacy. Combination strategies and next-generation engineered constructs are expected to overcome current barriers. This review summarizes the biological rationale, clinical evidence, safety considerations, and resistance mechanisms of TCR-T cell therapy in solid tumors and discusses future directions to optimize their therapeutic potential.